Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07048457 · ClinicalTrials.gov registry record · Phase 2
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
A Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07048457: Recruiting Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma, sponsored by Yale University.
NCT07048457 is a Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma that is actively recruiting participants, run by Yale University. The registered enrollment target is 32 participants, below the 125-participant average among 14 other Locally Advanced Urothelial Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07048457, a Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.
Primary Outcome
The primary outcome measure for this study is to evaluate the 12-month progression-free survival of consolidative therapy in participants with locally advanced or oligo-metastatic urothelial carcinoma (UC). PFS will be assessed by measuring the time from the initiation of consolidative therapy to the occurrence of disease progression or death from any cause, whichever comes first. The primary endpoint for this outcome measure is the one-year progression-free survival rate, which represents the
Conditions Studied
Interventions
- PROCEDURE Radical cystectomy
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
What NCT07048457 shows while recruiting
NCT07048457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 125-participant average among 14 other Locally Advanced Urothelial Carcinoma trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Locally Advanced Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radical cystectomy is the first listed.
NCT07048457 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07048457 about?
NCT07048457 is a clinical study titled "Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma". This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously rad...
What is the current status of trial NCT07048457?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-11-26. Estimated completion is 2028-11.
What conditions does trial NCT07048457 study?
This clinical trial studies the following conditions: Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma.
What interventions are being tested in trial NCT07048457?
The interventions under investigation include: Radical cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT07048457?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07048457 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07048457's enrollment target sits among peer trials
32 8th of 14 higher than 6 of 14 other Locally Advanced Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ARID1A and/or KDM6A Mutation and CXCL13 Expression
ACTIVE NOT RECRUITING · Phase 2
-
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
RECRUITING · Phase 1
-
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RECRUITING · Phase 3
-
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI